Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
Conditions: Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Albumin paclitaxel+trastuzumab+pyrrolitinib; Drug: Docetaxel+Carboplatin+trastuzumab+Parstuzumab Sponsor: Henan Cancer Hospital Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Docetaxel | HER2 | Herceptin | Hospitals | Neoadjuvant Therapy | Research | Taxotere